
CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and ...
The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemes The trial is expected to enroll 250 patients to receive treatment over 36 weeks BERKELEY HEIGHTS, N.J., April 15, 2025 (GLOBE NEWSWIRE …